Birznieks Gunther 4

What Happened

Gunther Birznieks, Senior Vice President, Business Development at Vanda Pharmaceuticals (VNDA), was granted 125,000 restricted stock units (RSUs) on February 18, 2026. The award is recorded as an acquisition (code A) at $0.00, so no cash changed hands. The filing (Form 4) was submitted on February 19, 2026.

Key Details

• Transaction date: 2026-02-18; Filing date: 2026-02-19 (timely; Form 4 typically due within 2 business days).
• Award: 125,000 RSUs; reported acquisition price $0.00 (total reported value $0).
• Shares owned after transaction: not disclosed in the filing.
• Footnote: RSUs vest in four equal annual installments; first vesting on March 1, 2027, subject to continued employment. Vested shares will be delivered on the first permissible trading day on or after each vest date.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax‑withholding detail, or sale/transfer noted in this filing.

Context

RSUs are time‑based compensation that convert to ordinary shares only as they vest; until then they are not tradable stock. This grant is a compensation award rather than an open‑market purchase or sale, so it reflects equity compensation practices rather than an immediate insider buy or sell.